The Brand Name NUPARIN Has Generic Salt :: Heparin 

NUPARIN  Is From Company Troikaa Priced :: Rs. 32.50/98.00

NUPARIN have Heparin is comes under Sub class Anti Coagulants of  Main Class Hematological System

Main Medicine Class:: Hematological System  Sub Medicine Class :: Anti Coagulants 

Indications for Drugs ::

Atrial fibrillation, Acute coronary syndrome, Unstable angina, Pulmonary embolism, Thromboembolism, Deep-vein thrombosis, Cardiopulmonary bypass, Hemofiltration, Peripheral arterial embolism

Drug Dose ::

Subcutaneous Venous thromboembolism Adult: 15,000 u injected every 12 hr. Child: 250 u/kg every 12 hr. Prophylaxis of postoperative venous thromboembolism Adult: 5000 u given 2 hr before surgery then every 8-12 hr for 7 days or until the patient is ambulant, may increase to 10,000 u every 12 hr during the 3rd trimester of pregnancy. Prophylaxis of mural thrombosis Adult: 12,500 u every 12 hr for at least 10 days. Intravenous Unstable angina Adult: 5000 u (10,000 u in severe pulmonary embolism) IV loading dose followed by 1000-2000 u/hr continuous infusion. Alternatively, intermittent inj of 5000-10,000 u every 4-6 hr. Child: Administer a lower loading dose. Maintenance: 15-25 u/kg/hr continuous infusion. Venous thromboembolism Adult: 5000 u (10,000 u in severe pulmonary embolism) IV loading dose followed by 1000-2000 u/hr continuous infusion. Alternatively, intermittent inj of 5000-10,000 u every 4-6 hr. Child: Administer a lower loading dose. Maintenance: 15-25 u/kg/hr continuous infusion. Peripheral arterial embolism Adult: 5000 u (10,000 u in severe pulmonary embolism) IV loading dose followed by 1000-2000 u/hr continuous infusion. Alternatively, intermittent inj of 5000-10,000 u every 4-6 hr. Child: Administer a lower loading dose. Maintenance: 15-25 u/kg/hr continuous infusion. Prophylaxis of re-occlusion of the coronary arteries following thrombolytic therapy in myocardial infarction Adult: 5000 u IV followed by 1000 u/hr IV with alteplase.

Contraindication ::

Patients predisposed to active bleeding including thrombocytopenia, peptic ulcer disease, cerebrovascular disorders, haemorrhagic blood disorders, bacterial endocarditis, severe hypertension, oesophageal varices. Recent surgery at sites where haemorrhage would be an especial risk. Severe renal and hepatic impairment. Cerebral or subarachnoid haemorrhage, abdominal or thoracic bleeding into closed space, severe traumatic bleed, hepatic, renal, splenic or arterial injury, severe haemostatic defect, arterial thrombosis with heparin-associated thrombocytopenia. IM admin.

Drug Precautions ::

Monitor platelet counts. Discontinue treatment if thrombocytopenia occurs. Hypersensitivity, elderly, pregnancy.

Drug Side Effects ::

Slight fever, headache, chills, nausea, vomiting, constipation, epistaxis, bruising, slight haematuria, skin necrosis (SC inj), osteoporosis, alopecia. Hypersensitivity reactions include urticaria, conjunctivitis, rhinitis, asthma, angioedema and anaphylactic shock. Priapism. Potentially Fatal: Heparin-induced thrombocytopenia with or without thrombosis; bleeding.

Pregnancy category ::

3

Drug Mode of Action ::  

Heparin increases the inhibitory action of antithrombin III (AT III) on clotting factors XIIa, XIa, IXa, Xa and thrombin. This inhibits the conversion of prothrombin to thrombin and fibrinogen to fibrin. It also inhibits platelet function. It may reduce the activity of ATIII at very high doses.

Drug Interactions ::

Enhanced anticoagulant effect w/ other drugs affecting platelet function or the coagulation system (e.g. platelet aggregation inhibitors, thrombolytic agents, salicylates, NSAIDs, vit K antagonists, dextrans, activated protein C). Decreased anticoagulant effect w/ gyceryl trinitrate infusion. Increased risk of hyperkalaemia w/ ACE inhibitors or angiotensin II antagonists.